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Abstract
Background: For the development of forecasts for seasonal allergic rhinitis symptoms, it is essential to understand
the relationship between grass pollen concentrations and the symptoms of grass pollen allergic patients.
Objective: The aim of this study was to delineate this relationship between seasonal allergic rhinitis symptoms and
grass pollen concentrations in the Netherlands.
Methods: Grass pollen allergic patients (n = 80 [2007] - 84 [2008]) were enrolled into the study. They were asked
to enter their seasonal allergic rhinitis symptoms (runny nose, sneezing, blocked nose, post nasal drip, and eye
symptoms) daily on a scale from 0 to 3 to the study centre either by short message service (SMS) or by internet
from May-July 2007 and April-July 2008. Daily pollen counts were used to define the early and the late grass pollen
season as the period ‘before and during’ respectively ‘after’ the first grass pollen peak (more than 150 pollen/m
3).
Results: At similar grass pollen concentrations, the daily mean of the individual maximum symptom scores
reported in the early season were higher as compared to that reported in the late season [differences of -0.41
(2007) and -0.30 (2008)]. This difference could not be explained by medication use by the patients nor by co-
sensitization to birch.
Conclusions: We conclude that seasonal allergic rhinitis symptoms at similar grass pollen concentrations are more
severe in the early flowering season as compared to those in the late flowering season. This finding is not only
relevant for development of forecasts for seasonal allergic rhinitis symptoms but also for understanding symptom
development and planning and analysis of clinical studies.
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Background
Allergic rhinitis is amongst the most common chronic
diseases of the world. It results from IgE-mediated
inflammation after allergen exposure of the nasal
mucosa and includes symptoms such as rhinorrhea,
nasal obstruction, nasal itching and sneezing [1]. The
majority of these patients (70-80%) also report ocular
symptoms [2].
Grass pollen exposure is one of the major causes of
allergic rhinitis in many parts of the world [3,4] The
grass family comprises more than 10,000 wind polli-
nated species world wide. Since these species flower in
succession, grass pollen is present in the air during a
relatively long period of approximately 3 months in
Western Europe. It has been shown that among at least
12 of these species the IgE-binding allergens involved
are very similar [5]. Since grass pollen allergic patients
respond to these different grass pollen species, they may
suffer from seasonal allergic rhinitis symptoms during a
relatively long period.
In the Netherlands, a daily symptom forecast for grass
pollen allergic patients is broadcasted by radio since
1980 [6] and is also published on Dutch Teletext and
the internet. Forecasts for seasonal allergic rhinitis
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and daily activities in order to reduce symptoms. For
accurate symptom forecasts it is relevant to understand
the relationship between grass pollen concentrations
and the symptoms of grass pollen allergic rhinitis during
the season. However, studies on the development of sea-
sonal allergic rhinitis symptoms in the course of the pol-
len season are scarce [7,8]. Despite the fact that
symptoms are recorded during the pollen season in
many clinical studies, and data from placebo treatment
could be used to study the symptom severity during the
season [9,10], so far this has not been reported. Further-
more, it should be noted that in most of these interven-
tion studies a selected patient population is studied with
more severe seasonal allergic rhinitis.
The aim of the present study was to delineate the rela-
tionship between grass pollen concentrations and symp-
tom severity in Dutch grass pollen allergic patients
during the season. Since the present study is part of a lar-
ger project that aims to develop a multi-day forecast for
seasonal allergic rhinitis symptoms that is not selectively
aimed at more severe patients, we recruited the patients
for this study by advertisements in the media (news
papers and radio) from the general population.
Methods
Study population
Patients aged between 18 - 60 years were recruited through
advertisement in local media. Since pollen counts can differ
in different regions of the Netherlands we included only
patients living in a region approximately 25 km around the
city of Leiden. All participants were subjected to: (i) screen-
ing of their medical history (general and allergy); (ii) perfor-
mance of skin prick tests with pollen (grass, elder, birch,
mugwort), house dust mite (Dermatophagoides pteronyssi-
nus and D. farinae), dog and cat (extracts were a kind gift
of HAL Allergy B.V); and (iii) a general physical examina-
tion and a nasal examination to exclude the existence of
nasal pathology interfering with the scoring of seasonal
allergic rhinitis symptoms. Patients with seasonal allergic
rhinitis symptoms during the grass pollen season and a
positive skin test to grass pollen, with or without mild
asthma (defined as treatment with bronchodilating b2-ago-
nists only) were included. Since only a minority of the
patients have mono grass pollen allergy we also enrolled
patients with a poly-sensitization in order to ensure exter-
nal validity. Participants were permitted oral antihistami-
nics, eye drops (antihistaminic, cromoglicate) and nasal
sprays (antihistaminic, cromoglicate, corticosteroid) for rhi-
noconjunctivitis treatment. Exclusion criteria were: (i) a
clinically relevant pet allergy and the very pet at home; (ii)
immunotherapy current and in the past; (iii) pregnancy or
breast feeding; (iv) daily use of inhaled corticosteroids for
asthma; (v) daily use of oral corticosteroids; (vi) other sig-
nificant co morbidity (e.g. severe cardiovascular or pul-
monary disease, malignancy, autoimmune diseases). In
2007, 80 patients were enrolled in the study. In 2008, 9
patients withdrew from this group due to migration or
pregnancy and 13 new patients were enrolled. The study
protocol was approved by the Medical Ethical Committee
o ft h eL e i d e nU n i v e r s i t yM e d i c a lC e n t e r( L U M C )a n d
patients signed an informed consent before enrolment.
Symptom scores
Symptoms scores were collected from May 15 until July 31
in 2007 (11 weeks) and from April 16 until July 31 in 2008
(15 weeks). The late start in symptom score collection in
2007 was due to the fact that study approval by the Medi-
cal Ethical Committee lagged behind schedule. Patients
were asked to submit daily symptom scores to the study
centre either by internet or by short message services
(SMS) between 5.00 PM and 8.30 AM. This tight time
frame was chosen in order to reduce recall bias. They
were asked to rate the severity of 5 seasonal allergic rhini-
tis symptoms (runny nose, sneezing, blocked nose, postna-
sal drip, and eye symptoms) on a four-point scale ranging
from zero (no symptoms) to three (severe symptoms).
Also the daily medication use was scored: number of oral
antihistaminics, number of eye drops, nasal spray, and
inhalation medication. Finally, patients reported whether
they spent the day in the region. The participants were
reminded every afternoon at 5.00 PM by a SMS from the
study centre to send in the scores.
Pollen counts
Pollen was collected by a Hirst type volumetric spore-
trap (Burkard Manufacturing Co. Limited, Hertfordshire,
England) located on the roof of the 6
th floor (approx
20 m above street level) of the LUMC [6]. The sampler
was operated weekly and the microscopic slides were
scanned in three longitudinal bands covering a total area
corresponding to 1 m
3 of sampled air in 24 h. The result-
ing counts are shown as average of daily pollen grains
per m
3 of air.
Statistical analysis
Compliance was calculated as the proportion of actual
entries in the database to the number of expected entries
per patient. Scores from outside the region were dis-
carded in the analysis. From the categorized symptom
scores daily means of the each one of the five symptom
scores were calculated (e.g. mean score for sneezing).
The daily mean medication use was calculated as the
average of the total medication use per patient per day.
Since there is substantial between-patient variation in
symptoms having the greatest clinical impact and our
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tions, we took the maximum score of either one of the
symptom scores per patient per day as individual mea-
sure of symptom severity. The maximum score per day
for either one of the symptoms can be considered as a
measure for the most relevant symptom for a particular
patient. Subsequently, we calculated the mean maximum
symptom score as a daily measure of severity of seasonal
allergic rhinitis for further analyses. All statistical ana-
lyses were performed with the statistical software package
Intercooled STATA 11.0 (StataCorp, TX, USA).
The grass pollen season in 2007 ran from May 24,
when 1% of annual sum was exceeded, to August 3, when
95% of total sum was reached. In 2008 the grass pollen
season ran from May 21 to July 30. The period was
defined as the early season, i.e. the period before and dur-
ing the first very high grass pollen concentrations (more
than 150 pollen/m
3), being before June 12
th and May 31
st
in 2007 and 2008, respectively. The late season was
defined as the period after the first grass pollen peak.
The relationship between the mean maximum symptom
score (dependent) and the grass pollen concentration
(independent) and the period (covariate) was analysed by
multiple linear regression analysis.
In addition we assessed whether a potential period effect
(i.e. late and early season) on the relationship between sea-
sonal allergic rhinitis symptoms and grass pollen concen-
tration could be explained by medication use or other
clinically relevant allergies. Therefore, we performed an
ordered logistic regression analysis with the individual
maximum symptom score as the dependent variable and
one confounding factor at a time in the model, clustered
by patient to account for repeated observations within
individuals (STATA, module ologit). The following factors
were included in the model: (i) the dichotomized daily
medication use per patient of either one of the permitted
medications; (ii) the dichotomized daily use of nasal ster-
oid spray for those patients using nasal steroid medication
to reduce their seasonal allergic rhinitis symptoms; (iii)
sensitization for birch pollen and house dust mite.
Furthermore, in order to assess whether a potential period
effect was influenced by allergic sensitization to house
dust mite or birch pollen, we included the interaction
term between period and the dichotomized allergic sensiti-
zation by skin prick tests for birch pollen (Birch
+)o rt h e
clinically relevant allergy for house dust mite (HDM
+)i n
the model. For the analysis with birch pollen sensitized
patients a dichotomised parameter for the birch pollen
season in 2008 (Birchseason) was included as 1 (April 15-
May 15) and 0 (May 16-July 31), based upon birch pollen
counts. In this analysis, 2007 was omitted since the birch
pollen season of 2007 had ended when the collection of
symptom scores started.
Results
Recruitment of patients
Relevant characteristics of the patients are listed in
Table 1. In the skin prick test 19 (2007) and 18 (2008)
percent of the patients responded exclusively to grass
pollen, 65% to birch pollen, 55.5% to alder pollen, 12%
to mugwort pollen and 30% to house dust mite. Accord-
ing to patient self-reports, oral antihistamines were the
most frequently used medication (Table 1).
Symptom scores
Patients sent in their daily symptoms scores either by
S M S( 2 1 . 7 % )o rb yi n t e r n e t( 7 8 . 3 % ) .A l t h o u g hi tw a s
p a r t l ys u m m e rh o l i d a ys e a s o n ,t h ec o m p l i a n c eo ft h e
patient group was high. During the 11 week-period in
2007 and the 15 week-period in 2008 the compliance
was 78.8% and 77.3%.
The daily mean scores of each of the five symptoms dur-
ing the season show a similar temporal pattern (e.g. eye
symptoms and sneezing in Figure 1). In addition, the
severity of the five symptoms correlate with the daily pol-
len counts, showing high symptom scores at high pollen
concentration and low symp t o m ss c o r e sa tl o wp o l l e n
concentrations (Figures 1, 2). Indeed, there was a signifi-
cant relationship between daily pollen counts and the dif-
ferent symptom scores with the correlation coefficients
ranging from 0.60 to 0.65 (p < 0.001) in 2007 and from
0.51 to 0.55 (p < 0.001) in 2008. Also, the daily mean med-
ication use showed a similar temporal pattern, with higher
medication use during days with high pollen counts and
severe symptoms and reduced medication use on days
with low pollen counts and milder symptom severity
( F i g u r e1 ) .T h ec o r r e l a t i o ncoefficient between pollen
counts and mean medication use was 0.57 (p < 0.001) in
2007 and 0.63 (p < 0.001) in 2008.
Table 1 Characteristics of the patient group
2007 2008
Number 80 84
Mean age (SD) 33.5 (9.6) 34.5 (10.1)
Sex (M/F) 30/50 33/51
Mono grass pollen allergy
1 19 18
Medication use
2
Oral antihistamine 63 65
Nasal antihistamine 4 3
Nasal cromoglicate 4 8
Nasal steroid 16 19
Eye drops antihistamine 5 9
Eye drops cromoglicate 8 9
Inhalation medication 5 3
1Number of patients exclusively positive in the skin prick test for grass pollen
2Number of patients indicating their specific medication use during the
anamnesis
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(0.67-1.89) and 1.16 (0.56 - 2.03) in 2007 and 2008,
respectively. The mean maximum symptoms score was
significantly correlated wi t he a c ho ft h ef i v es y m p t o m
scores with a correlation coefficient ranging from 0.86
for postnasal drip to 0.96 for sneezing. (p < 0.001) The
correlation coefficient between the mean maximum
symptom score and pollen count was 0.61 and 0.51 in
2007 and 2008, respectively, (p < 0.001).
Figure 2 shows that in both years the symptoms
scores at the beginning of the season in May after the
first grass pollen exposure appeared to be higher than
scores reported at similar grass pollen concentrations at
the end of the season. This phenomenon was analysed
in more detail. A multiple regression analysis with the
mean maximum symptom score (dependent), the pollen
(independent) and the period, i.e. the early and the late
season (covariate), showed a significant period effect (p
< 0.001). At similar grass pollen concentrations, symp-
toms were higher in the early season compared to the
late season (difference: -0.41 [95% CI -0.42 to -0.40];
and -0.30 [95% CI -0.32 to -0.29] for 2007 and 2008,
respectively). This is reflected by the observation that
the relationship between the daily mean maximum
symptom score and the daily pollen concentration is dif-
ferent in the two periods (Figure 3). The regression
Figure 1 Daily grass pollen counts and daily mean scores for sneezing, eye symptoms and medication use during the grass pollen
season in 2007 and 2008.
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and 2008, respectively.
Although medication use itself had an independent
effect on maximum symptom scores (OR ≥ 2.77; p <
0.001), analyses with or without medication use revealed
similar proportional odds ratios of the period effect
(table 2). Therefore, medication use does not seem to be
a confounder of the period effect. The mean maximum
symptom scores showed a positive correlation with daily
mean medication use (Figure 4), reflecting medication
Figure 2 Daily mean of the maximum symptom score (line) in 2007 (a) and 2008 (b). The bars show the daily grass pollen counts. The
season is split into an early and late season on June 12
th in 2007 and May 31
st in 2008 (indicated by arrows).
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of symptoms. However, since frequent use of nasal ster-
oids might have a long-term effect on symptoms, we
assessed whether steroid use could explain the period
effect. For both years, the proportional odds ratio of the
period was not significantly affected by this potential
confounder (table 2). The ordered logistic analysis in
which patients using steroids were excluded showed
similar results (proportional odds ratio for the period
0.43 [0.33-0.57] and 0.48 [0.37-0.61] for 2007 and 2008
respectively) as the analysis with the complete patient
group (see table 2). These analyses show that neither
the use of nasal steroids nor medication use in general
explain the difference in symptom scores at similar
grass pollen concentrations between the two periods of
the season (table 2).
The grass pollen season is preceded by the birch pollen
season. Since 65 percent of the patients were co-sensitized
Figure 3 Scatter plot of the daily mean of the maximum symptom score and the pollen concentrations in the early (open circles) and
the late season (closed circles) of 2007 (a) and 2008 (b). Regression lines are shown for the early season (dashed line) and for the late
season (solid line).
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tion was performed. This analysis did not show an effect
of co-sensitization for birch pollen on maximum symptom
scores in neither the 2007 nor the 2008 season (p > 0.1,
table 3). Therefore, priming by birch pollen does not seem
to be a confounder of the period effect. However, since
the end of the birch pollen season and the start of the
2008 grass pollen season overlapped, we performed a stra-
tified analysis of the group of patients co-sensitized to
birch pollen and the overlapping birch and grass pollen
period. This analysis showed a trend of an effect of birch
pollen sensitization for this period on maximum symptom
scores (p = 0.089). However, the proportional odds ratio
of the period was not significantly affected (table 3). A
stratified analysis of patients with mono grass pollen
allergy did neither significantly influence maximum symp-
tom scores nor did it explain the period effect (data not
shown). Similar results were found in a stratified analysis
with patients with a clinically relevant house dust mite
allergy (see table 3).
Discussion
I nt h ep r e s e n ts t u d yw ef o u n dthat grass pollen allergic
patients have more severe symptoms in the early season
compared to the late season at similar grass pollen con-
centrations. This seasonal effect could not be explained
by any of the confounding factors including self-reported
medication use, co-sensitization to birch pollen and a
clinically relevant house dust mite allergy.
In this study, the between-day variations in five sepa-
rate types of symptoms (runny nose, sneezing, blocked
nose, postnasal drip, and eye symptoms) were summar-
ized by the mean maximum symptom score. By selecting
ap a t i e n t ’s maximum symptom score, irrespective of the
nature of the symptom, we were able to monitor the day-
to-day variations in seasonal allergic rhinitis symptoms
severity (see Figure 2). The late start of the symptom
score collection in 2007 resulted in a lower number of
observations in the early season compared to that period
in 2008. A major drawback of this late start is the fact
that the overlap in birch and grass pollen season could
not be studied in this study year (see below). However,
the results of 2007 and 2008 were consistent in showing
more severe symptoms in the early season compared to
the late season at similar grass pollen concentrations.
It was relevant to study whether the difference in
symptom scores in the early and the late season of the
grass pollen season that we observed could be due to
confounding factors, such as the use of medication and
co-sensitization to birch pollen or house dust mite in the
patients. Although this latter could have been avoided by
including primarily mono grass pollen sensitized patients,
those patients appeared to be very rare. We also consid-
ered the possibility that a more regular medication use in
the late period could reduce symptom severity. However,
the ordered logistic regression analysis showed that
Table 2 Analysis of confounding factors related to medication use by ordered logistic regression with pollen and the
period and one confounding factor at a time.
Confounding Factor Factors of analysis 2007 2008
Proportional
Odds Ratio (95%CI)
P-value Proportional
Odds Ratio (95%CI)
P-value
- Period
a 0.40 (0.32-0.50) < 0.001 0.49 (0.40-0.61) < 0.001
Medication Period 0.42 (0.33-0.53) < 0.001 0.48 (0.39-0.60) < 0.001
Medication use
b 2.77 (1.74-4.43) < 0.001 3.57 (2.47-5.17) < 0.001
Nasal steroid Period
a 0.40 (0.31-0.51) < 0.001 0.48 (0.38-0.59) < 0.001
Nasal steroid
c 1.51 (0.76-2.97) 0.24 2.43 (1.26-4.70) 0.008
The proportional odds ratio, the 95% confidence interval (CI) and the p values for the period and the confounding factor for each model are shown for 2007a n d
2008.
a The period refers to the late (index) versus the early season (reference) of the grass pollen season.
bMedication use refers to the daily use of any medication for hay fever symptoms (index) versus no use of medication (reference).
cNasal steroid refers to the daily use of nasal steroid spray (index) versus no use of nasal steroid spray (reference).
Figure 4 The relationship between daily mean medication use
and daily mean maximum symptom scores of the patient
group in both the 2007- and 2008 pollen season (r = 0.84, p <
0.001).
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response to grass pollen. On the contrary, the patients
using medication appeared to suffer from more severe
symptoms than the patients who did not use medication.
Furthermore, the self-reported medication use increased
with increasing mean maximum symptom score (Figure 4),
suggesting that the patients took their medication mainly
on demand.
Birch co-sensitization appeared to significantly contri-
bute to the maximum symptom score in 2008, when
the birch pollen season overlapped with the start of the
symptom collection and the grass pollen season. This
result can be explained, because patients co-sensitized
to birch pollen may respond in the overlapping season
to the presence of birch pollen, while grass pollen con-
centrations are still low. However, the birch pollen sen-
sitivity did not influence the period effect significantly
(table 3). Therefore, we conclude that neither of these
confounding factors could fully explain the differences
in response to similar grass pollen concentrations
between the early and the late season. Also selective
loss of patients (e.g. mild patients in the early season)
can be excluded as a cause for the observed difference
in symptom scores between the early and late season,
since the compliance among all patients in the group
was very high (78.8% and 77.3% in 2007 and 2008,
respectively).
The ICT based system by which the daily symptoms
were recorded and transferred to the study centre at the
end of each day by internet or by SMS, is a novel
approach. In most studies symptom scores are collected
using a weekly questionnaireo rad i a r y[ 1 1 ] .T h i sm a y
lead to missing data and the data may contain a recall
bias.
Very diverse explanations may account for the
observed findings. The first could be the occurrence of a
few days with very high grass pollen concentrations in
the early season. Patients that experienced severe symp-
toms during this period may consider their symptoms on
subsequent days in the late season much less severe. Sec-
ondly, during the season different grass species start to
flower and produce pollen. Although the allergenic deter-
m i n a n t so fm a j o ra l l e r g e n so fg r o u p1a n d5a r ev e r y
similar in at least 12 grass pollen species studied
5,t h e
content of allergens (allergenic potency) of the grass pol-
len of different species may vary between those that pro-
duce pollen in the early versus the late season. The lower
symptom score in the late season may be a reflection of
the difference in the allergic response to the early and the
late flowering species. Finally, according to the concept of
priming, repeated exposure of the nasal tissue to allergen
may cause a non-specific up-regulation of mucosal sensi-
tivity and responsiveness [12,13] However, this priming
effect is not reported consistently [14-18]. Most
Table 3 Analysis of effect modifiers related to the allergic sensitization of the patients by ordered logistic regression
with pollen and the period and the effect modifier(s)
Effect modifier Factors for analysis 2007 2008
Proportional
Odds Ratio (95% CI)
P-value Proportional
Odds Ratio (95%CI)
P-value
- Period
a 0.40 (0.32-0.50) < 0.001 0.49 (0.40-0.60) < 0.001
Birch sensitization Period
a 0.32 (0.21-0.48) < 0.001 0.53 (0.36-0.77) < 0.001
Birch
+b 0.71 (0.31-1.59) 0.40 1.26 (0.64-2.48) 0.51
Birch
+
*period 1.40 (0.83-2.38) 0.20 0.91 (0.56-1.44) 0.68
Birch sensitization and pollen season Period
a ND
d 0.52 (0.36-0.76) < 0.001
Birch
+b ND 1.22 (0.61-2.43) 0.58
Birchseason
c ND 0.92 (0.58-1.49) 0.76
Birch sensitization and pollen season Period
a ND
d 0.54 (0.43-0.68) < 0.001
Birch
+b ND 0.97 (0.59-1.58) 0.90
Birchseason
c ND 0.89 (0.65-1.23) 0.49
Birch
+
*Birchseason ND 1.48 (0.94-2.33) 0.09
HDM Period
a 0.38 (0.29-0.50) < 0.001 0.52 (0.41-0.66) < 0.001
HDM
e 0.73 (0.27-1.93) 0.52 1.25 (0.55-2.84) 0.59
HDM * period 1.27 (0.78-2.08) 0.34 0.68 (0.39-1.18) 0.17
The proportional odd ratio, the 95% confidence interval (CI) and the p values for the period and the effect modifier for each model are shown for 2007 and
2008.
a The period refers to the late (index) versus the early season (reference) of the grass pollen season.
bBirch
+ refers to patients that are co-sensitized to birch pollen (index) versus patients with a negative skin prick test for birch pollen (reference).
cBirchseason refers to the birch pollen season (index) versus the period outside the birch pollen season (reference).
dND = not determined since in 2007 the birch pollen season was over by the time the symptoms collection started.
eHDM refers to patients with a clinically relevant house dust mite allergy (index) versus patients without an house dust mite allergy (reference).
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and the effect of repeated exposure beyond 2 weeks is
not well known [12]. It has been suggested that especially
grass pollen allergic patients may have a natural potential
to down regulate their allergic response after repeated
allergen exposure [14]. The high exposure to grass pollen
in the end of the early season may result in a decrease in
allergic inflammation during subsequent exposures in the
late season. Whether mechanisms similar to those
observed after immunotherapy, i.e. an increase in block-
ing antibodies and regulatory T cells [19,20], are impli-
cated in this decreased inflammation is unknown.
However, the observation of an increase in Foxp3+ T
regulatory cells in the nasal mucosa of patients during
the grass pollen season compared to patients outside the
season [21] indeed suggests that allergen-specific regula-
tory T cells reduce the allergic response during the late
season.
Conclusion
We found strong evidence that grass pollen allergic
patients have more severe symptoms in the early season
compared to the late season at similar grass pollen con-
centrations. This finding has implications for our under-
standing of symptom development and for clinical
studies during the grass pollen season. A difference in
response to grass pollen during the study period may
interfere with the outcome of such clinical studies. Care-
ful planning of such studies is crucial for adequate inter-
pretation of the results. Furthermore our findings have
implications for the development of forecasts for seaso-
nal allergic rhinitis symptoms. The different response to
grass pollen during the grassp o l l e ns e a s o ns h o u l db e
taken into account when the forecast of seasonal allergic
rhinitis symptoms is based on expected grass pollen
counts.
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